DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections

Information source: NIH AIDS Clinical Trials Information Service
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Mycoses; HIV Infections

Intervention: Fluconazole (Drug); Amphotericin B (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Pfizer

Summary

To compare the safety, tolerance and efficacy of fluconazole and amphotericin B as treatment for biopsy proven fungal infections in major organs, disseminated infection, suspected fungal infection and fungemia in adult neutropenic and non-neutropenic patients without AIDS, AIDS related complex (ARC), or extensive burns. HIV seropositive patients are allowed only if they also have a malignancy.

Clinical Details

Official title: Fluconazole Versus Amphotericin B: A Prospective, Randomized, Multicenter Study for Therapy of Fungal Infection

Study design: Treatment

Eligibility

Minimum age: 13 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria

Concurrent Medication:

Allowed:

- Immunostimulants under studies carried out under an IRB approved protocol.

- Treatments of intercurrent non-fungal infection.

- Allowed but requires monitoring during fluconazole therapy:

- Barbiturates.

- Phenytoin.

- Oral hypoglycemics.

- Coumarin-type anticoagulants.

Patients must have the following:

- Diagnosis or presumption of fungal infection under defined conditions.

- Written informed consent either from the patient or the patient's legal guardian.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

- Burns > 30 percent of the body.

- Diagnosis of AIDS or AIDS related complex (ARC).

- HIV positive unless they have a malignancy.

- History of allergy to or intolerance of imidazoles or azoles.

- Moderate to severe liver disease as defined by specific lab values.

- Unlikely to survive more than 24 hours.

- Evidence of previous amphotericin B sensitivity.

Concurrent Medication:

Excluded:

- Concomitant antifungal agents other than the study drugs.

- Immunostimulants, except for studies carried out under an IRB approved protocol.

Concurrent Treatment:

Excluded:

- Lymphocyte replacements.

Patients with the following are excluded:

- Defined disease conditions listed in Exclusion Co-Existing Conditions.

- Unlikely to survive more than 24 hours.

- Previous participation in this study; reentry for the same infection is not allowed.

- Known to be unable to take amphotericin B due to acute toxicities.

Prior Medication:

Excluded:

- Previous fluconazole therapy for this infection.

Locations and Contacts

M D Anderson Cancer Ctr, Houston, Texas 77030, United States

Dr Layne Gentry, Houston, Texas 77030, United States

Dr Temple Williams, Houston, Texas 77030, United States

Additional Information


Last updated: June 23, 2005

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009